Is CG Oncology Inc. (CGON) a Buy, Sell, or Hold?
CG Oncology Inc.
NASDAQ:CGON
$71.77 USD
-$0.73 (-1.01%)
- Volume
- 1.11M
- Average Volume
- 1.07M
- Market Capitalization
- $6.33B
- P/E Ratio
- -30.67
- Dividend Yield
- 0.00%
- Price Target
- $81.00
- Year High
- $77.00
- Year Low
- $23.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $31.30
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Arthur Kuan |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CGON |
| CUSIP | 156944100 |
| CIK | 0001991792 |
| Web | https://cgoncology.com |
| Phone | +1 949 354 1630 |
| Currency | USD |
| Employees | 142 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 31.30 |
| Quick Ratio | 31.25 |
| Cash Ratio | 0.96 |
Sales & Book Value
| Annual Sales | $4.04M |
| Price / Sales | 1248.33 |
| Cash Flow | -1.90 |
| Price / Cash Flow | -39.46 |
| Price / Book | 5.56 |
Price Target and Rating
| Average Stock Price Forecast | $81.00 |
| High Stock Price Forecast | $90.00 |
| Low Stock Price Forecast | $70.00 |
| Forecast Upside/Downside | -11.40% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.08 |
| Trailing P/E Ratio | -30.67 |
| PEG Ratio | 0.78 |
| P/E Growth | 0.78 |
| Net Income | $-161M |
| Net Margin | -3682.61% |
| Pretax Margin | -3682.61% |
| Return on Equity | -23.33% |
| Return on Assets | -16.45% |
Financials Score
| AltmanZ Score | 87.10 |
| Piotroski Score | 4.00 |
| Working Capital | 1.07B |
| Total Assets | 1.14B |
| Ebit | -186.74M |
| Market Cap | 6.31B |
| Total Liabilities | 43.48M |
Poll Results
About CG Oncology Inc. (NASDAQ:CGON) Stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also d ... evelops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
2026-07-13 10:07:02
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
2026-06-10 03:02:38
CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-muscle invasive bladder cancer, or NMIBC.
2026-06-09 17:52:11
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
2026-06-07 17:06:19
CG Oncology NASDAQ: CGON is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York.
CG Oncology to Present at Upcoming Investor Conferences in June
2026-05-28 16:05:00
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference
2026-05-20 22:05:23
CG Oncology NASDAQ: CGON executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company's investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones.
2026-05-19 08:00:00
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year's awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the recipients of the second annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
2026-05-15 08:00:00
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively
Frequently Asked Questions
-
What is the current CG Oncology Inc. (CGON) stock price?
-
CG Oncology Inc.(NASDAQ:CGON) stock price is $71.77 in the last trading session. During the trading session, CGON stock reached the peak price of $77 while $23.65 was the lowest point it dropped to. The percentage change in CGON stock occurred in the recent session was --1.01% while the dollar amount for the price change in CGON stock was -$-0.73.
-
CGON's industry and sector of operation?
-
The NASDAQ listed CGON is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CGON?
-
Arthur Kuan | President, Chairman & CEO
Vijay Kasturi | Chief Medical Officer
Ambaw Bellete | Chief Operating Officer
James DeTore | Chief Financial Officer
Bing Kung | Vice President of Corporate Development -
How many employees does CGON have?
-
Number of CGON employees currently stands at 142. CGON operates from 400 Spectrum Center Drive, Irvine, CA 92618, US.
-
Link for CGON official website?
-
Official Website of CGON is: https://cgoncology.com
-
How do I contact CGON?
-
CGON could be contacted at phone #+1 949 354 1630 and can also be accessed through its website. CGON operates from 400 Spectrum Center Drive, Irvine, CA 92618, US.
-
How many shares of CGON are traded daily?
-
The average number of CGON shares traded daily for last 3 months was 1.07M.
-
What is the market cap of CGON currently?
-
The market value of CGON currently stands at $6.33B with its latest stock price at $71.77